De Braud, F.; Deschler-Baier, B.; Morris, J.C., III; Worden, F.; Han, Y.; Kiiskinen, U.; Jen, M.-H.; Barker, S.S.; Szymczak, S.; Gilligan, A.M.
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001. Cancers 2024, 16, 140.
https://doi.org/10.3390/cancers16010140
AMA Style
De Braud F, Deschler-Baier B, Morris JC III, Worden F, Han Y, Kiiskinen U, Jen M-H, Barker SS, Szymczak S, Gilligan AM.
Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001. Cancers. 2024; 16(1):140.
https://doi.org/10.3390/cancers16010140
Chicago/Turabian Style
De Braud, Filippo, Barbara Deschler-Baier, John C. Morris, III, Francis Worden, Yimei Han, Urpo Kiiskinen, Min-Hua Jen, Scott S. Barker, Sylwia Szymczak, and Adrienne M. Gilligan.
2024. "Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001" Cancers 16, no. 1: 140.
https://doi.org/10.3390/cancers16010140
APA Style
De Braud, F., Deschler-Baier, B., Morris, J. C., III, Worden, F., Han, Y., Kiiskinen, U., Jen, M. -H., Barker, S. S., Szymczak, S., & Gilligan, A. M.
(2024). Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001. Cancers, 16(1), 140.
https://doi.org/10.3390/cancers16010140
